Mineralocorticoid

Global Congenital Adrenal Hyperplasia Market Report to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022
Biotechnology, Pharmaceutical, Health, Androgen, Disease, 21-Hydroxylase, Review, Diagnosis, Infant, Congenital adrenal hyperplasia, Patient, CAH, Research, Enzyme, Adrenal crisis, Genetic distance, Aldosterone, Kidney, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency, Mineralocorticoid, Awareness, Birth defect, Hormone, Death, Exocrine gland, Algorithm, Pharmaceutical industry

It covers the details of conventional and current medical therapies and diagnoses available in the congenital adrenal hyperplasia (CAH) market to treat the condition.

Key Points: 
  • It covers the details of conventional and current medical therapies and diagnoses available in the congenital adrenal hyperplasia (CAH) market to treat the condition.
  • The congenital adrenal hyperplasia (CAH) Market Report gives a thorough understanding of congenital adrenal hyperplasia (CAH) by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • It also provides the treatment algorithms and treatment guidelines for congenital adrenal hyperplasia (CAH) in the US, Europe, and Japan.
  • The launch of emerging therapies will significantly impact the congenital adrenal hyperplasia (CAH) market.

Propella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022

Retrieved on: 
Thursday, September 8, 2022
Metastasis, Neoplasm, Safety, Steroid, Cancer, Survival, Liver, Therapy, Prostate cancer, Man, Lymphatic system, Tissue, CYP17, Hypokalemia, Mineralocorticoid, Lymph, Progesterone, Hypertension, Edema, Androgen, Risk, Testosterone, Moa, Growth, Patient, Travel, Pharmaceutical industry, Medical imaging

PRL-02 is currently in an open-label, multi-center Phase 1/2 study for the treatment of metastatic prostate cancer.

Key Points: 
  • PRL-02 is currently in an open-label, multi-center Phase 1/2 study for the treatment of metastatic prostate cancer.
  • Prostate cancer is the most common non-skin cancer in men, and the second leading cause of cancer death, developing most often in older men.
  • While early or localized prostate cancer remains highly curable, advanced prostate cancer) remains difficult to treat, with a 5-year survival rate of only 30%.
  • Propella is currently in the Phase 1 portion of a Phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer.

Congenital Adrenal Hyperplasia Epiomic Epidemiology Forecasts 2018-2028

Retrieved on: 
Monday, September 17, 2018
Adrenal gland disorders, Medicine, Endocrine system, Endocrinology, Congenital adrenal hyperplasia, Adrenal gland, Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, Mineralocorticoid, Cytochrome P450 reductase, Glucocorticoid, Steroid, Lipoid congenital adrenal hyperplasia

The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Congenital Adrenal Hyperplasia Forecast In 31 Major Markets 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • Congenital adrenal hyperplasia (CAH) is a group of genetic disorders associated with deficiencies of several adrenal enzymes which lead to abnormal production of glucocorticoids, mineralocorticoids and sex steroids.
  • This, in turn, affects metabolism, sodium and water balance and the development of primary or secondary sex characteristics.
  • CAH can occur in classic (severe) or non-classic (mild) forms depending on the amount of residue enzyme activity.